Navigation Links
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
Date:3/15/2013

ression patients in our ongoing NSI-189/major depressive disorder (MDD) Phase Ib trial. Dosing has now increased from 40 mg. q.d.(once/day) for 28 days, which had been shown to be well-tolerated and safe in the first cohort, to 40 mg. b.i.d.(twice/day) for 28 days. Dosing of all patients in the second cohort will be completed this month and, pending FDA approval, we will commence dosing the final cohort."

Neuralstem's President and CEO Richard Garr added, "Neuralstem continued to strengthen its patent estate in 2012. Among the highlights, U.S. Patent number 8,236,299 includes claims covering processes for dissociating our neural stem cells from CNS tissue; culturing the cells; expanding the cells in vitro, and transplanting the cells into the spinal cord of a patient to treat a wide array of neurodegenerative conditions, including ALS, chronic and acute spinal cord injury, and stroke. Both the substance and life of this patent (into 2030) are reflective of the Intellectual Property value we are creating in our cell therapy programs. Additionally, during the past 12 months we have executed the first two out-licenses of our spinal platform cell therapy technology."

"Dr. Johe and I would like to extend our continued deep appreciation to our patients, their families and caregivers, our world-class clinical collaborators, and the Neuralstem team for enabling positive, ground-breaking clinical work which has now positioned us to move forward," added Garr.

Business Highlights for 2012 Cellular Therapy: NSI-566 Phase I Clinical Trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig 's disease) at Emory University Hospital

  • Neuralstem completed the final surgery of its Phase I NSI-566/ALS trial in August. The trial proved the safety of the company's proprietary technology, the cells and proprietary intraspinal surgical procedure. Data presented at the International
    '/>"/>

  • SOURCE Neuralstem, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
    2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
    3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
    4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
    5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
    6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
    7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
    8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
    9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/15/2014)... Bioptigen announced today the availability ... the optical device metrology and pre-clinical ophthalmic research markets. ... for Contact Lens Metrology is designed for non-destructive, non-contact, ... lens, IOL structures, and donor tissues. The ... immersed in a hydration bath (saline), automated segmentation of ...
    (Date:9/15/2014)... Research and Markets has announced the ... by Services, by Technology, by Application - Global Forecast to ... Exome Sequencing (WES) is next-generation technology used for strategically sequencing ... exome, which is the total of all exons of an ... actually converted into proteins after translation. It is responsible for ...
    (Date:9/15/2014)... Die zweite jährliche International Plasma ... 18. Oktober stattfinden. Die IPAW ist eine gemeinsame ... (PPTA) und ihrer Mitgliedsunternehmen und hat ... für die Gewinnung von Quellplasma zu steigern ... Verbessern von Leben zu würdigen , Das ...
    (Date:9/15/2014)... , Sept. 15, 2014  The second annual ... celebrated October 12-18. A joint initiative of the ... member companies , IPAW is designed to: ... , Recognize the contributions of plasma donors in saving ... plasma protein therapies and rare diseases ...
    Breaking Biology Technology:Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
    ... 6 CryoLife, Inc., (NYSE: ... processing company, today announced that it has received a Humanitarian ... (FDA) for its CryoValve® SG aortic human heart valve. ... Humanitarian Device Exemption (HDE) for the CryoValve SG aortic human ...
    ... , PALO ALTO, Calif., Oct. 6 Varian, Inc. (NasdaqGS: VARI) ... October 5, 2009, its stockholders adopted the merger agreement entered ... Varian for $52.00 per share in cash. Approximately 84% ... August 12, 2009, the record date for the special meeting, ...
    ... ... today announced its sole focus of delivering novel nanotechnology solutions for instantly assessing ... world, without requiring a costly, complex medical infrastructure. , ... Santa Barbara, CA (PRWEB) October ...
    Cached Biology Technology:CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 3CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 4Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 2Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 3Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 4
    (Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
    (Date:9/15/2014)... When this week,s print issue of the journal ... up from New Mexico, Montana and even the Netherlands, ... more and more the norm in these connected times. ... it will produce innovations in biology, medicine, biotechnology and ... this scientist talked with that one, that one knew ...
    (Date:9/15/2014)... A new strategic vision document, released today by ... describes the long-term goals, objectives, and strategies for ... work over the next five years (2015-2020). ... short-term activities, to be funded in 2015, will ... policy fellowships. , The $500 million, 30-year ...
    Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Collaboration drives achievement in protein structure research 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
    ... researchers have proved that eating strawberries reduces the harm ... Published in the open access journal Plos One, the ... ulcers. A team of Italian, Serbian and Spanish ... in a mammal stomach that has been damaged by ...
    ... of a brain protein that regulates gene expression may play ... and sometimes disabling psychiatric disease. As reported in the latest ... International Society for Bipolar Disorders, levels of SP4 (specificity protein ... in postmortem samples from patients with bipolar disorder. The study ...
    ... latest issue of Elsevier,s Materials Today , researchers ... of carbon nanotubes to create mechanical components for use ... industry has excelled in miniaturizing components, with individual elements ... reducing the size of mechanical systems has proved much ...
    Cached Biology News:Strawberries protect the stomach from alcohol 2Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3Nanotubes key to microscopic mechanics 2
    Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
    ... 2000 One-Step FP Standardization Kit is ... low fluorescence polarization values of fluorescein ... Beacon 2000 System. It also allows ... generated by their instrument to the ...
    Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
    Biology Products: